Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
2006 pubmed 74 citations

Prostaglandin/cyclooxygenase pathway in ghrelin-induced gastroprotection against ischemia-reperfusion injury.

Brzozowski. Tomasz T; Konturek. Peter C PC; Sliwowski. Zbigniew Z; Pajdo. Robert R; Drozdowicz. Danuta D; Kwiecien. Slawomir S; Burnat. Grzegorz G; Konturek. Stanislaw J SJ; Pawlik. Wieslaw W WW

Key Findings

  • Peripheral or central ghrelin reduced stomach lesions after ischemia‑reperfusion injury in rats.
  • The protective effect depended on GHS‑R1a receptor activation, vagal nerve signaling, and the COX‑prostaglandin system.
  • COX‑1 and COX‑2 inhibitors (e.g., indomethacin, rofecoxib) weakened ghrelin’s protection, but adding a prostaglandin analog restored it.

Practical Outcomes

  • For biohackers using GHRP‑6 or other ghrelin‑activating peptides, the study suggests a potential side benefit of stomach protection, especially under acute stress. However, taking strong NSAIDs may blunt this protective effect. The findings are based on animal models, so human relevance is uncertain, but they support the idea that maintaining vagal tone and prostaglandin production could enhance gastrointestinal resilience.

Summary

In rats, giving ghrelin (or activating its receptor) helped protect the stomach lining from damage caused by a brief loss of blood flow and then reperfusion. This protection involved better blood flow, more protective prostaglandins, and less oxidative stress, and it required an intact vagus nerve. Blocking the ghrelin receptor or using COX‑inhibiting drugs reduced the benefit, showing the pathway is essential for the effect.

Abstract

Ghrelin is involved in the control of food intake, but its role in gastroprotection against the formation of gastric mucosal injury has been little elucidated. We studied the effects of peripheral (i.p.) and central (i.c.v.) administration of ghrelin on gastric secretion and gastric mucosal lesions induced by 3 h of ischemia/reperfusion (I/R) with or without inhibition of ghrelin growth hormone secretagogue type 1a receptor (GHS-R1a) by using ghrelin antagonist, d-Lys(3)-GHRP-6; blockade of cyclooxygenase (COX)-1 (indomethacin, SC560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole]) and COX-2 (rofecoxib); and bilateral vagotomy or capsaicin denervation. I/R produced typical gastric erosions, a significant fall in the gastric blood flow (GBF), an increase in gastric myeloperoxidase (MPO) activity and malonyldialdehyde (MDA) content, and the up-regulation of mucosal ghrelin mRNA. Ghrelin dose-dependently increased gastric acid secretion and significantly reduced I/R-induced gastric erosions, while producing a significant rise in the GBF and mucosal PGE(2) generation and a significant fall in MPO activity and MDA content. The protective and hyperemic activities of ghrelin were significantly attenuated in rats pretreated with d-Lys(3)-GHRP-6 and capsaicin denervation and completely abolished by vagotomy. Indomethacin, SC560, and rofecoxib, selective COX-1 and COX-2 inhibitors, attenuated ghrelin-induced protection that was restored by supplying the methyl analog of prostaglandin (PG) E(2). The expression of mRNA for COX-1 was unaffected by ghrelin, but COX-2 mRNA and COX-2 protein were detectable in I/R injured mucosa and further up-regulated by exogenous ghrelin. We conclude that ghrelin exhibits gastroprotective and hyperemic activities against I/R-induced erosions, the effects that are mediated by hormone activation of GHS-R1a receptors, COX-PG system, and vagal-sensory nerves.

Study Information

Provider

pubmed

Year

2006

Date

2006-07-25T00:00:00.000Z

DOI

10.1124/jpet.106.105932

Citations

74

References

49